Local
Blood Test May Offer New Window Into Alzheimer’s Progression
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Medscape
A new ultrasensitive blood test has shown promise for identifying advanced tau pathology in Alzheimer’s disease (AD) and may offer a more scalable way to assess disease stage and severity. In a cross-sectional study, a plasma immunoassay for endogenously cleaved microtubule-binding region tau (eMTBR-tau) accurately identified advanced tau pathology in the brain and performed comparably to a more complex mass spectrometry method. This “scalable immunoassay could broaden research access and support clinical evaluation,” the authors wrote. The study was presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference and published online on November 16 in JAMA. Strong Tie to Tau Pathology Plasma phosphorylated tau 217 (p-tau217), a measure of soluble tau pathology, is increasingly used to identify AD-related amyloid pathology but is less specific for the insoluble tau tangles that more closely track neurodegeneration and cognitive decline.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Medscape



